Literature DB >> 12588663

Umbilical cord mannan-binding lectin and infections in early childhood.

S Kielgast1, S Thiel, T B Henriksen, T Bjerke, J Olsen, J Chr Jensenius.   

Abstract

To investigate whether mannan-binding lectin (MBL) in umbilical cord blood (UCB) is associated with the incidence rate of hospitalizations for infections during early childhood. A follow-up study from birth to 31 months of age, with endpoint data from the Danish National Hospital Discharge Registry. The concentration of MBL and immunoglobulin A (IgA) in UCB was measured in a time-resolved immunofluorometric assay. Information on possible confounding factors was obtained from questionnaires completed by mothers during their pregnancy, and characteristics of the child at birth were registered by a midwife on a structured coding sheet. A total of 2104 infants born in the period between 1 February 1990 and 25 May 1991 to mothers living in the municipality of Aarhus. Concentration of MBL and IgA in UCB, gestational age, birth weight, number of siblings less than 3 years old, mother's smoking habits, alcohol and coffee consumption, educational and marital status and previous spontaneous abortions and stillbirths. Of 2104 children, 626 were hospitalized at least once, and 346 of these were hospitalized with infection. The hazard ratio (HR) of hospitalization with infections in children with low levels of MBL (<120 ng/ml) was 1.4 (95% confidence interval (CI), 1.0-1.8), which was similar to our findings on hospitalization because of other diseases. The HR of hospitalization for viral infections was 2.8 (CI, 1.3-5.9). Low levels of MBL in UCB were associated with hospitalization in general and particularly with hospitalization for viral infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588663     DOI: 10.1046/j.1365-3083.2003.01202.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  High prevalence of mannose-binding lectin (MBL) deficiency in premature neonates.

Authors:  F N J Frakking; N Brouwer; D Zweers; M P Merkus; T W Kuijpers; M Offringa; K M Dolman
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 2.  Factors of the lectin pathway of complement activation and their clinical associations in neonates.

Authors:  Maciej Cedzynski; Anna St Swierzko; David C Kilpatrick
Journal:  J Biomed Biotechnol       Date:  2012-03-22

Review 3.  The mannose-binding lectin: a prototypic pattern recognition molecule.

Authors:  Kazue Takahashi; Wk Eddie Ip; Ian C Michelow; R Alan B Ezekowitz
Journal:  Curr Opin Immunol       Date:  2005-12-20       Impact factor: 7.486

4.  Genetic and other factors determining mannose-binding lectin levels in American Indians: the Strong Heart Study.

Authors:  Lyle G Best; Robert E Ferrell; Susan Decroo; Kari E North; Jean W Maccluer; Ying Zhang; Elisa T Lee; Barbara V Howard; Jason Umans; Vittorio Palmieri; Peter Garred
Journal:  BMC Med Genet       Date:  2009-01-22       Impact factor: 2.103

5.  Possible disease-modifying factors: the mannan-binding lectin pathway and infections in hereditary angioedema of children and adults.

Authors:  Maciej Cedzyński; Kazimierz Madaliński; Hanna Gregorek; Anna S Swierzko; Ewa Nowicka; Krystyna Obtułowicz; Katarzyna Dzierzanowska-Fangrat; Urszula Wojda; Daniel Rabczenko; Masaya Kawakami
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-02-05       Impact factor: 4.291

6.  Antimicrobial peptide LL-37 and recombinant human mannose-binding lectin express distinct age- and pathogen-specific antimicrobial activity in human newborn cord blood in vitro.

Authors:  Annette Scheid; Ning Li; Carleen Jeffers; Francesco Borriello; Sweta Joshi; Al Ozonoff; Matthew Pettengill; Ofer Levy
Journal:  F1000Res       Date:  2018-05-21

7.  Mannose-binding lectin cord blood levels and respiratory symptoms during infancy: a prospective birth cohort study.

Authors:  Luregn Jan Schlapbach; Philipp Latzin; Nicolas Regamey; Claudia E Kuehni; Marcel Zwahlen; Carmen Casaulta; Christoph Aebi; Urs Frey
Journal:  Pediatr Allergy Immunol       Date:  2008-08-12       Impact factor: 6.377

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.